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ally in Saudi Arabia from October to March.
Premature infants born at less than 29 weeks gestation with chronic lung disease or those
with significant congenital heart disease who have RSV infection are more likely to be hospi-
talized and have increased morbidity and mortality. Palivizumab (Synagis, Medimmune) is a
humanized monoclonal antibody for the prevention of severe LRTI by RSV in high-risk children.
The current use of Palivizumab in Saudi Arabia is not regulated and does not meet approved
standards.
This clinical practice policy statement was developed by the Ministry of Health and is sup-
ported by the National Immunization Technical Advisory Group (NITAG) in Saudi Arabia. It is
based on available national and international data on the use of Palivizumab for the prevention
of severe LRTI caused by RSV in high-risk pediatric patients. These guidelines were solicited
and endorsed by two Saudi societies: The Neonatology and the Pediatric Infectious Diseases
Societies.Health, Neonatal Services Improvement Program, P.O. Box 59046, Riyadh 11525, Saudi Arabia.
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Year City/province Hospital
1993 Riyadh KKUHa
1998 Riyadh KFSHRCb
1998 Riyadh KKUH
2002 Riyadh KKUH
2004 Mecca-Hajj KAUH-Jeddah
2005 Abha ACHd
2005 Riyadh KKUH
2006 Al-Qassim BMPHeCopyright ª 2016, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Respiratory Syncytial Virus (RSV) is a single-stranded,
non-segmented RNA negative-sense virus belonging to
the Pneumovirinea subfamily of the Paramyxoviridae
family. It has two subtypes, A and B, which are distin-
guished largely by differences in the viral attachment (G)
protein and the nuclear (N) protein. During epidemics,
either subtype may predominate, or both subtypes may
circulate concurrently [1].
RSV is unstable in the environment and is readily
inactivated by soap and water. The virus spreads through
close contact with infected carriers or contaminated
surfaces. Infection occurs when contaminated materials
come in contact with the mucous membranes of the eyes,
nose or mouth. It can remain infectious on surfaces or
fomites for 4e7 h and can survive on unwashed hands
[2,3].
The main therapy for RSV in infants is supportive. Pal-
ivizumab (Synagis), a human monoclonal antibody
directed against the fusion protein F of RSV (conserved
among isolates), is produced by recombinant DNA tech-
nology and was licensed for use in RSV prophylaxis in June
1998 by the United States Food and Drug Administration for
the reduction of serious lower respiratory tract infection
caused by RSV in children at increased risk of severe disease
[4e6].
This clinical practice policy statement was developed
by the Ministry of Health and supported by the National
Immunization Technical Advisory Group (NITAG) in Saudi
Arabia based on all available national and recent inter-
national data for the use of Palivizumab for the preven-
tion of severe LRTI caused by RSV in high-risk pediatric
patients.
The Saudi Pediatrics Infectious Diseases Society (SPIDS)
and the Saudi Neonatology Society (SNS) have endorsed
these RSV prophylaxis guidelines. These guidelines shall be
reviewed and updated every 2 years as needed. The Min-
istry of Health laboratories will monitor changes in RSV
seasons (see Table 1).ducted in Saudi Arabia [14].
No of samples Detection tes
127 IFAg
256 ND
1429 ND
20 NDh
c 500 IFA
51 ELISAi/IFA
4575 IFA
282 IFA2. Purpose of the guidelines
1. Implement national guidelines on RSV immunoprophy-
laxis to reduce variations across the country and limit
Palivizumab to a specific high-risk population on the
basis of available evidence, as well as expert opinion.
2. To be a resource for healthcare professionals (HCPs)
involved in the management of an RSV Immunoprophy-
laxis Program.
3. Improve the utilization of resources and enhance cost-
effective practices.
3. Epidemiology
RSV is a highly contagious virus that causes serious global
outbreaks. The virus results in significant morbidity and
mortality in infants during the first year of life, and nearly
all infants experience one or more RSV infections by the
end of their second year [2]. The disease severity ranges
from a mild upper respiratory tract infection (URTI) to a
severe lower respiratory tract infections (LRTI). Globally,
RSV is estimated to have caused 66,000 to 199,000 pneu-
monia deaths in children younger than 5 years in 2005. In
the United States, the hospitalization rate is 2345 per
100,000 person-years for RSV compared to 151 for influ-
enza, consistent with reports that RSV hospitalizes 1e2% of
infants each winter [7,8].
In Saudi Arabia, RSV was reported to be the main cause
of LRTI in infants in more than one study [1,9e13], ac-
counting for up to 40% of all LRTIs in children aged <1 year
and up to 83% in children aged <5 years. Most cases occur
from November through March, but infections have been
reported in other months in Saudi Arabia [6,11]. Most RSV
infections are mild and require minimal hospital stays;
however, some children are severely affected, requiring
pediatric ICU admission and a longer hospital stay. Risk
factors for serious infection with RSV include prematurity;
bronchopulmonary dysplasia (BPD); cyanotic congenital
heart disease; and immunodeficiency diseases or immuno-
suppression caused by therapy [12].t HRSV positive No. (%) Type Ref.
69 (54)k e Jamjoom et al
73(28.5) e Al-Hajjar et al [9]
412 (79) e Bakir et al [11]
8 (40) e Kilani
4 (7.4) e Bakhly et al
20 (40) e Al-shehri et al [10]
884 (19) e Sheir and Mona
128 (45) e Meqdam and Sobaih
(continued on next page)
Table 1 (continued )
Year City/province Hospital No of samples Detection test HRSV positive No. (%) Type Ref.
2009 Riyadh KAMCf 10,617 IFA 733 (83) e Akhter et al [2]
2009 Riyadh KKUHa 200 RT-PCRj 70 (35) A(57%)B(42.9%) Al-majhdi et al [1]
a King Khalid University Hospital.
b King Faisal Specialist Hospital and Research Centre.
c King Abdulaziz University Hospital.
d Assir Central Hospital.
e Buraidah Maternity and Pediatric Hospital.
f King Abdulaziz Medical City.
g Immunofluorescent assay.
h Not defined.
i Enzyme linked immunosorbent assay.
j Reverse transcription polymerase chain reaction.
k Percentage was calculated on the basis of respiratory samples of confirmed viral origin.
40 F. Al Aql et al.4. Definitions
RSV season in this policy is defined as the period of time
during which the prevalence of the infection increases.
Although this varies among regions and nations according to
seasonality, in Saudi Arabia the onset usually occurs in
middle to late October and ends in early to mid-March [6].
Chronic lung disease (CLD) (also known as broncho-
pulmonary dysplasia) of prematurity was defined as oxy-
gen dependency at 36 weeks corrected gestational age (GA)
for babies delivered at less than 32 weeks GA [4].
5. Policy statement [4,15e20]
1. RSV clinics shall dispense RSV prophylaxis from the
middle of October until the middle of March.
2. Palivizumab prophylaxis shall be administered to all
infants born before 29 weeks gestation who are
younger than 12 months at the start of the RSV
season.
3. Palivizumab prophylaxis must not be administered to
healthy infants born at 29 weeks gestation or more
who are free of CLD, as they experience a lower RSV
hospitalization rate than preterm infants born at <29
weeks gestation.
4. Prophylaxis must be given in the first year of life for
preterm infants with BPD.
5. Infants with certain hemodynamically significant
heart diseases (a cyanotic heart disease under med-
ical support and moderate to severe pulmonary hy-
pertension) should also be given RSV prophylaxis.
6. Children with immunocompromised conditions, cystic
fibrosis, pulmonary abnormalities or neuromuscular
disease should not routinely be offered Palivizumab
because of limited and inconclusive data. However,
prophylaxis may be considered for children younger
than 24 months of age with pulmonary abnormality or
neuromuscular disease that impairs the ability to
clear secretions from the upper airways, infants who
are on home oxygen, who have had a prolonged
hospitalization for severe pulmonary disease or who
are severely immunocompromised.
7. Palivizumab should be administered up to a maximum
of 5 monthly doses (15 mg/kg per dose administeredintramuscularly once every 30 days) during the RSV
season to infants who qualify for prophylaxis in the
first year of life. A child with a history of a severe
allergic reaction following a dose of Palivizumab
should not receive additional doses.
8. Qualified infants born during the RSV season must
receive fewer doses according to their month of
birth. For example, infants born in January would
receive their last dose in March.
9. Palivizumab prophylaxis should not be administered
in the second year of life except for children who
require supplemental oxygen at 36 weeks corrected
gestational age who also continue to require medical
intervention (supplemental oxygen, chronic cortico-
steroid treatment, or diuretic therapy) in the six
months prior to the second season.
10. Monthly prophylaxis should be discontinued in any
child who experiences a breakthrough RSV
hospitalization.
11. Palivizumab prophylaxis is not recommended for the
prevention of health care-associated RSV disease.
12. Injection Palivizumab should be stored in a refriger-
ator at 2 Ce8 C.
13. To reduce the risk for RSV and other viral infections,
all infants, especially preterm infants, should be
offered breast milk. The parents should be instructed
to avoid smoke exposure, attendance at large group
childcare during the first winter season and contact
with ill people.
14. It is recommended that household members should be
immunized against influenza and practice good hand
and cough hygiene.
15. Palivizumab is not approved or recommended for the
treatment of RSV disease.
16. Palivizumab does not interfere with routine childhood
immunizations.6. Procedure
6.1. Preparation of palivizumab (synagis) [5].
1. Obtain Palivizumab Injection from the refrigerator and
dilute the powder using water for injection.
Guidelines for palivizumab prophylaxis among infants and young children in Saudi 412. Use 1 ml of water for injection of a 100 mg vial of Pal-
ivizumab, and 0.6 ml for a 50 mg vial, for a final con-
centration of 100 mg/ml.
3. Slowly add the water along the inside wall of the vial to
minimize foaming. Tilt the vial slightly and gently rotate
the vial for 30 s. DO NOT SHAKE THE VIAL.
4. Leave the Palivizumab solution at room temperature for
a minimum of 20 min until the solution clarifies.
5. Because the Palivizumab does not contain any pre-
servatives, it must be administered within 3 h of
preparation.
6.2. Administration of palivizumab [5].
1. Verify the patient identity and data.
2. Calculate the dose to be administered according to the
weight. The dose should be 15 mg/kg.
3. For example:
Weight 15mg
100mg
Zml to be administered
4. Obtain the required amount of injection and administer
intramuscularly in the anterolateral aspect of the thigh
using standard aseptic technique. The gluteal muscle is
not preferred as an injection site because of the risk of
sciatic nerve damage.
5. Administer the injection volumes over 1 ml as a divided
dose.
6. Palivizumab is contraindicated in patients with hyper-
sensitivity to the active substance or other humanized
monoclonal antibodies.
7. Keep all equipment needed for the treatment of severe
hypersensitivity reactions ready before the administra-
tion of prophylaxis.
8. Do not reconstitute Palivizumab with any other diluents
or medicinal components.
9. Educate the mother regarding adverse effects such as
fever, nervousness and diarrhea, which are common
post-administration of prophylaxis. All side effects
should be reported to the Saudi Food and Drug
Authority.
10. Document the patient details and the date of adminis-
tration in the RSV log book and card.
It should be noted that Palivizumab does not interfere with
the immune response to other live or inactivated vaccines
and the childhood immunization schedule should be fol-
lowed for all children, regardless of Palivizumab use.
Furthermore, more effort should be made to monitor data
for the seasonality of RSV circulation and disease burden in
various regions of Saudi Arabia and to fully investigate the
burden of RSV among Saudi children.Conflicts of interest
No conflicts of interest are reported.Ethical approval
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